Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial

Area of Science:

• Pharmacology
• Addiction Medicine
• Clinical Research

Background:

• Medical detoxification is crucial for opioid dependence treatment but current methods have limitations.
• Opioid antagonist medications have shown inconsistent results in improving detoxification.
• Very low dose naltrexone (VLNTX) has demonstrated potential in reducing opioid tolerance and dependence.

Purpose of the Study:

• To evaluate the safety and efficacy of VLNTX as an adjunct to methadone for reducing withdrawal symptoms during opioid detoxification.
• To assess the impact of VLNTX on craving and adverse events in patients undergoing detoxification.

Main Methods:

• A multi-center, double-blind, randomized study involving 174 opioid-dependent subjects.
• Participants received tapering doses of methadone along with daily VLNTX (0.125 mg or 0.250 mg) or placebo for 6 days.
• Withdrawal symptoms, craving, retention rates, and adverse events were monitored.

Main Results:

• VLNTX-treated individuals reported significantly attenuated withdrawal symptoms (P = 0.001) and reduced craving (P = 0.03).
• Treatment effects were more pronounced at the time of discharge.
• No significant differences in retention rates, use of adjuvant medications, or treatment-related adverse events were observed between groups.

Conclusions:

• VLNTX adjunct to methadone appears safe and effective in reducing withdrawal symptoms and craving during opioid detoxification.
• Further research is warranted to explore VLNTX in combination with opioid agonist medications for both detoxification and long-term opioid dependence treatment.